Secondary and Exploratory Outcomes of the Subthreshold Nanosecond Laser Intervention Randomized Trial in Age-Related Macular Degeneration: A LEAD Study Report

Z Wu; CD Luu; LAB Hodgson; E Caruso; KH Brassington; N Tindill; KZ Aung; CA Harper; SS Wickremasinghe; SS Sandhu; MB McGuinness; FK Chen; U Chakravarthy; JJ Arnold; WJ Heriot; SR Durkin; MWM Wintergerst; S Gorgi Zadeh; T Schultz; RP Finger; AC Cohn; EK Baglin; P Sharangan; RH Guymer

Journal article

Secondary and Exploratory Outcomes of the Subthreshold Nanosecond Laser Intervention Randomized Trial in Age-Related Macular Degeneration: A LEAD Study Report

Z Wu, CD Luu, LAB Hodgson, E Caruso, KH Brassington, N Tindill, KZ Aung, CA Harper, SS Wickremasinghe, SS Sandhu, MB McGuinness, FK Chen, U Chakravarthy, JJ Arnold, WJ Heriot, SR Durkin, MWM Wintergerst, S Gorgi Zadeh, T Schultz, RP Finger Show all

Ophthalmology Retina | ELSEVIER INC | Published : 2019

DOI: 10.1016/j.oret.2019.07.008

Abstract

Purpose: To evaluate the secondary and exploratory outcomes of the Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study, a 36-month trial of a subthreshold nanosecond laser (SNL) treatment for slowing the progression to late age-related macular degeneration (AMD) in its early stages. Design: Multicenter, randomized, sham-controlled trial. Participants: Two-hundred ninety-two patients with bilateral large drusen. Methods: Participants were randomly assigned to receive SNL or sham treatment to the study eye at 6-month intervals. Main Outcome Measures: The secondary outcome measure of the LEAD study was the time to development of late AMD, defined by multimodal im..

View full abstract

University of Melbourne Researchers

Chi Luu Author

Alex Harper Author

Sanj Wickremasinghe Author

Myra McGuinness Author

Grants

Awarded by Bupa Health Foundation

Funding Acknowledgements

Supported by National Health & Medical Research Council of Australia (project grant APP1027624 [R.H.G. and C.D.L.], and fellowship grant GNT1103013 (R.H.G.), APP1104985 [Z.W.], APP1054712 [F.K.C.], APP1142962 [F.K.C.] and GNT1128343 [S.S.W.]), and BUPA Health Foundation (Australia) (R.H.G. and C.D.L.). The Centre for Eye Research Australia receives operational infrastructure support from the Victorian Government. Ellex R&D Pty Ltd. (Adelaide, Australia) provided partial funding of the central coordinating center and the in-kind provision of Ellex 2RT~ laser systems, ongoing support of those systems, and the Macular Integrity Assessment microperimeters for the duration of the study. The web-based Research Electronic Data Capture (REDCap) application and open-source platform OpenClinica allowed secure electronic data capture. The study is sponsored by the Centre for Eye Research Australia, an independent medical research institute and a not-for-profit company.